BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 18851683)

  • 1. Epigenetics, DNA methylation, and chromatin modifying drugs.
    Szyf M
    Annu Rev Pharmacol Toxicol; 2009; 49():243-63. PubMed ID: 18851683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone deacetylation in epigenetics: an attractive target for anticancer therapy.
    Mai A; Massa S; Rotili D; Cerbara I; Valente S; Pezzi R; Simeoni S; Ragno R
    Med Res Rev; 2005 May; 25(3):261-309. PubMed ID: 15717297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic targeting in pancreatic cancer.
    van Kampen JG; Marijnissen-van Zanten MA; Simmer F; van der Graaf WT; Ligtenberg MJ; Nagtegaal ID
    Cancer Treat Rev; 2014 Jun; 40(5):656-64. PubMed ID: 24433955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel approaches on epigenetics.
    Papait R; Monti E; Bonapace IM
    Curr Opin Drug Discov Devel; 2009 Mar; 12(2):264-75. PubMed ID: 19333872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small molecule modulators in epigenetics: implications in gene expression and therapeutics.
    Swaminathan V; Reddy BA; Ruthrotha Selvi B; Sukanya MS; Kundu TK
    Subcell Biochem; 2007; 41():397-428. PubMed ID: 17484138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
    Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
    J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetics in prostate cancer: biologic and clinical relevance.
    Jerónimo C; Bastian PJ; Bjartell A; Carbone GM; Catto JW; Clark SJ; Henrique R; Nelson WG; Shariat SF
    Eur Urol; 2011 Oct; 60(4):753-66. PubMed ID: 21719191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting epigenetic networks with polypharmacology: a new avenue to tackle cancer.
    Franci G; Miceli M; Altucci L
    Epigenomics; 2010 Dec; 2(6):731-42. PubMed ID: 22122079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA methyltransferase inhibitor RG108 and histone deacetylase inhibitors cooperate to enhance NB4 cell differentiation and E-cadherin re-expression by chromatin remodelling.
    Savickiene J; Treigyte G; Jazdauskaite A; Borutinskaite VV; Navakauskiene R
    Cell Biol Int; 2012 Nov; 36(11):1067-78. PubMed ID: 22845560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Promises and challenges of anticancer drugs that target the epigenome.
    Verbrugge I; Johnstone RW; Bots M
    Epigenomics; 2011 Oct; 3(5):547-65. PubMed ID: 22126246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylase inhibitor and demethylating agent chromatin compaction and the radiation response by cancer cells.
    Bar-Sela G; Jacobs KM; Gius D
    Cancer J; 2007; 13(1):65-9. PubMed ID: 17464248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switching on epigenetic therapy.
    Karberg S
    Cell; 2009 Dec; 139(6):1029-31. PubMed ID: 20005793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic mechanisms in AML - a target for therapy.
    Oki Y; Issa JP
    Cancer Treat Res; 2010; 145():19-40. PubMed ID: 20306243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How to build a centromere: from centromeric and pericentromeric chromatin to kinetochore assembly.
    Vos LJ; Famulski JK; Chan GK
    Biochem Cell Biol; 2006 Aug; 84(4):619-39. PubMed ID: 16936833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer.
    Zhong S; Fields CR; Su N; Pan YX; Robertson KD
    Oncogene; 2007 Apr; 26(18):2621-34. PubMed ID: 17043644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetics of autoimmune diabetes.
    Jayaraman S
    Epigenomics; 2011 Oct; 3(5):639-48. PubMed ID: 22126251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting aberrant chromatin structure in colorectal carcinomas.
    Konishi K; Issa JP
    Cancer J; 2007; 13(1):49-55. PubMed ID: 17464246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The emerging role of epigenetic modifications and chromatin remodeling in spinal muscular atrophy.
    Lunke S; El-Osta A
    J Neurochem; 2009 Jun; 109(6):1557-69. PubMed ID: 19383090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic therapy--a new development in pharmacology.
    Peedicayil J
    Indian J Med Res; 2006 Jan; 123(1):17-24. PubMed ID: 16567863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic interplay between histone modifications and DNA methylation in gene silencing.
    Vaissière T; Sawan C; Herceg Z
    Mutat Res; 2008; 659(1-2):40-8. PubMed ID: 18407786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.